O	0	5	Human	Human	JJ	B-NP
O	6	20	papillomavirus	papillomavirus	NN	I-NP
O	21	32	oncoprotein	oncoprotein	NN	I-NP
O	33	35	E6	E6	NN	I-NP
O	36	47	inactivates	inactivate	VBZ	B-VP
O	48	51	the	the	DT	B-NP
O	52	67	transcriptional	transcriptional	JJ	I-NP
O	68	79	coactivator	coactivator	NN	I-NP
O	80	85	human	human	JJ	I-NP
O	86	90	ADA3	ADA3	NN	I-NP
O	90	91	.	.	.	O

O	93	97	High	High	JJ	B-NP
O	97	98	-	-	HYPH	I-NP
O	98	102	risk	risk	NN	I-NP
O	103	108	human	human	JJ	I-NP
O	109	125	papillomaviruses	papillomavirus	NNS	I-NP
O	126	127	(	(	(	O
O	127	131	HPVs	HPV	NNS	B-NP
O	131	132	)	)	)	O
O	133	136	are	be	VBP	B-VP
O	137	147	associated	associate	VBN	I-VP
O	148	152	with	with	IN	B-PP
B-Cancer	153	163	carcinomas	carcinoma	NNS	B-NP
O	164	166	of	of	IN	B-PP
O	167	170	the	the	DT	B-NP
B-Multi-tissue_structure	171	177	cervix	cervix	NN	I-NP
O	178	181	and	and	CC	O
O	182	187	other	other	JJ	B-NP
B-Cancer	188	195	genital	genital	JJ	I-NP
I-Cancer	196	202	tumors	tumor	NNS	I-NP
O	202	203	.	.	.	O

O	204	207	The	The	DT	B-NP
O	208	211	HPV	HPV	NN	I-NP
O	212	223	oncoprotein	oncoprotein	NN	I-NP
O	224	226	E6	E6	NN	I-NP
O	227	229	is	be	VBZ	B-VP
O	230	239	essential	essential	JJ	B-ADJP
O	240	243	for	for	IN	B-PP
O	244	253	oncogenic	oncogenic	JJ	B-NP
O	254	268	transformation	transformation	NN	I-NP
O	268	269	.	.	.	O

O	270	272	We	We	PRP	B-NP
O	273	281	identify	identify	VBP	B-VP
O	282	286	here	here	RB	B-ADVP
O	287	292	hADA3	hADA3	NN	B-NP
O	292	293	,	,	,	O
O	294	299	human	human	JJ	B-NP
O	300	309	homologue	homologue	NN	I-NP
O	310	312	of	of	IN	B-PP
O	313	316	the	the	DT	B-NP
O	317	322	yeast	yeast	NN	I-NP
O	323	338	transcriptional	transcriptional	JJ	I-NP
O	339	350	coactivator	coactivator	NN	I-NP
O	351	356	yADA3	yADA3	NN	I-NP
O	356	357	,	,	,	O
O	358	360	as	as	IN	B-PP
O	361	362	a	a	DT	B-NP
O	363	368	novel	novel	JJ	I-NP
O	369	371	E6	E6	NN	I-NP
O	371	372	-	-	HYPH	O
O	372	383	interacting	interact	VBG	B-VP
O	384	391	protein	protein	NN	B-NP
O	392	395	and	and	CC	O
O	396	397	a	a	DT	B-NP
O	398	404	target	target	NN	I-NP
O	405	407	of	of	IN	B-PP
O	408	410	E6	E6	NN	B-NP
O	410	411	-	-	HYPH	B-NP
O	411	418	induced	induce	VBN	I-NP
O	419	430	degradation	degradation	NN	I-NP
O	430	431	.	.	.	O

O	432	437	hADA3	hADA3	NN	B-NP
O	438	443	binds	bind	VBZ	B-VP
O	444	455	selectively	selectively	RB	B-ADVP
O	456	458	to	to	TO	B-PP
O	459	462	the	the	DT	B-NP
O	463	467	high	high	JJ	I-NP
O	467	468	-	-	HYPH	I-NP
O	468	472	risk	risk	NN	I-NP
O	473	476	HPV	HPV	NN	I-NP
O	477	479	E6	E6	NN	I-NP
O	480	488	proteins	protein	NNS	I-NP
O	489	492	and	and	CC	O
O	493	497	only	only	RB	B-ADVP
O	498	500	to	to	TO	B-PP
O	501	516	immortalization	immortalization	NN	B-NP
O	516	517	-	-	HYPH	B-NP
O	517	526	competent	competent	JJ	I-NP
O	527	529	E6	E6	NN	I-NP
O	530	537	mutants	mutant	NNS	I-NP
O	537	538	.	.	.	O

O	539	544	hADA3	hADA3	NN	B-NP
O	545	554	functions	function	VBZ	B-VP
O	555	557	as	as	IN	B-PP
O	558	559	a	a	DT	B-NP
O	560	571	coactivator	coactivator	NN	I-NP
O	572	575	for	for	IN	B-PP
O	576	579	p53	p53	NN	B-NP
O	579	580	-	-	HYPH	O
O	580	588	mediated	mediate	VBN	B-NP
O	589	604	transactivation	transactivation	NN	I-NP
O	605	607	by	by	IN	B-PP
O	608	619	stabilizing	stabilize	VBG	B-VP
O	620	623	p53	p53	NN	B-NP
O	624	631	protein	protein	NN	I-NP
O	631	632	.	.	.	O

O	633	640	Notably	Notably	RB	B-ADVP
O	640	641	,	,	,	O
O	642	647	three	three	CD	B-NP
O	648	661	immortalizing	immortalize	VBG	I-NP
O	662	664	E6	E6	NN	I-NP
O	665	672	mutants	mutant	NNS	I-NP
O	673	677	that	that	WDT	B-NP
O	678	680	do	do	VBP	B-VP
O	681	684	not	not	RB	I-VP
O	685	691	induce	induce	VB	I-VP
O	692	698	direct	direct	JJ	B-NP
O	699	702	p53	p53	NN	I-NP
O	703	714	degradation	degradation	NN	I-NP
O	715	718	but	but	CC	O
O	719	721	do	do	VBP	B-VP
O	722	730	interact	interact	VB	I-VP
O	731	735	with	with	IN	B-PP
O	736	741	hADA3	hADA3	NN	B-NP
O	742	749	induced	induce	VBD	B-VP
O	750	753	the	the	DT	B-NP
O	754	764	abrogation	abrogation	NN	I-NP
O	765	767	of	of	IN	B-PP
O	768	771	p53	p53	NN	B-NP
O	771	772	-	-	HYPH	B-NP
O	772	780	mediated	mediate	VBN	I-NP
O	781	796	transactivation	transactivation	NN	I-NP
O	797	800	and	and	CC	I-NP
O	801	802	G	G	NN	I-NP
O	802	803	(	(	(	O
O	803	804	1	1	CD	O
O	804	805	)	)	)	O
B-Cell	806	810	cell	cell	NN	B-NP
O	811	816	cycle	cycle	NN	I-NP
O	817	823	arrest	arrest	NN	I-NP
O	824	829	after	after	IN	B-PP
O	830	833	DNA	DNA	NN	B-NP
O	834	840	damage	damage	NN	I-NP
O	840	841	,	,	,	O
O	842	852	comparable	comparable	JJ	B-ADJP
O	853	855	to	to	TO	B-PP
O	856	860	wild	wild	JJ	B-NP
O	860	861	-	-	HYPH	I-NP
O	861	865	type	type	NN	I-NP
O	866	868	E6	E6	NN	I-NP
O	868	869	.	.	.	O

O	870	875	These	These	DT	B-NP
O	876	884	findings	finding	NNS	I-NP
O	885	891	reveal	reveal	VBP	B-VP
O	892	893	a	a	DT	B-NP
O	894	899	novel	novel	JJ	I-NP
O	900	908	strategy	strategy	NN	I-NP
O	909	911	of	of	IN	B-PP
O	912	915	HPV	HPV	NN	B-NP
O	916	918	E6	E6	NN	I-NP
O	918	919	-	-	HYPH	B-NP
O	919	926	induced	induce	VBN	I-NP
O	927	931	loss	loss	NN	I-NP
O	932	934	of	of	IN	B-PP
O	935	938	p53	p53	NN	B-NP
O	939	947	function	function	NN	I-NP
O	948	952	that	that	WDT	B-NP
O	953	955	is	be	VBZ	B-VP
O	956	967	independent	independent	JJ	B-ADJP
O	968	970	of	of	IN	B-PP
O	971	977	direct	direct	JJ	B-NP
O	978	981	p53	p53	NN	I-NP
O	982	993	degradation	degradation	NN	I-NP
O	993	994	.	.	.	O

O	995	1000	Given	Give	VBN	B-PP
O	1001	1004	the	the	DT	B-NP
O	1005	1011	likely	likely	JJ	I-NP
O	1012	1016	role	role	NN	I-NP
O	1017	1019	of	of	IN	B-PP
O	1020	1023	the	the	DT	B-NP
O	1024	1038	evolutionarily	evolutionarily	RB	I-NP
O	1039	1048	conserved	conserve	VBN	I-NP
O	1049	1054	hADA3	hADA3	NN	I-NP
O	1055	1057	in	in	IN	B-PP
O	1058	1066	multiple	multiple	JJ	B-NP
O	1067	1078	coactivator	coactivator	NN	I-NP
O	1079	1088	complexes	complex	NNS	I-NP
O	1088	1089	,	,	,	O
O	1090	1102	inactivation	inactivation	NN	B-NP
O	1103	1105	of	of	IN	B-PP
O	1106	1109	its	its	PRP$	B-NP
O	1110	1118	function	function	NN	I-NP
O	1119	1122	may	may	MD	B-VP
O	1123	1128	allow	allow	VB	I-VP
O	1129	1131	E6	E6	NN	B-NP
O	1132	1134	to	to	TO	B-VP
O	1135	1142	perturb	perturb	VB	I-VP
O	1143	1151	numerous	numerous	JJ	B-NP
B-Cell	1152	1160	cellular	cellular	JJ	I-NP
O	1161	1169	pathways	pathway	NNS	I-NP
O	1170	1176	during	during	IN	B-PP
O	1177	1180	HPV	HPV	NN	B-NP
O	1181	1192	oncogenesis	oncogenesis	NN	I-NP
O	1192	1193	.	.	.	O

